Article successfully added.

CyFlow™ CD266 PE

CyFlow™ CD266 PE
Alternative Name: Fn14, TNFRSF12A, TWEAK R
Antibody: Yes
Antigen: CD266
Application: Flow cytometry
Clonality: monoclonal
Clone: ITEM-4
Emission Maximum: 576 nm
Excitation Maximum: 496 nm, 565 nm
Field of Interest: Apoptosis, Immunophenotyping
Format/Fluorochrome: PE
Isotype: IgG2b
Laser: Blue , Green, Yellow
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human, Mouse
Product number: AD595460

For Research Use Only

$255.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Concentration Unit mg/mL Concentration 0,1 Quantity 0.1 mg Volume 1.0 mL... more
Close menu
CyFlow™ CD266 PE
Concentration Unitmg/mL
Concentration0,1
Quantity0.1 mg
Volume1.0 mL
ImmunogenHuman CD266-transfected P815 cells
Background InformationCD266 (TWEAK R, TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14), is a receptor for CD255 (TWEAK), the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.
UsageThe reagent is designed for Flow Cytometry analysis. Working concentrations should be determined by the investigator.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor‑inducible 14 mediates multiple pathways of TWEAK‑induced cell death. J Immunol. 2003 Jan 1; 170(1):341‑8. < PMID: 12496418 > | Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF‑like weak inducer of apoptosis differentially activate the classical and noncanonical NF‑kappa B pathway. J Immunol. 2010 Aug 1; 185(3):1593‑605. < PMID: 20610643 > | Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan; 2(1):103‑108. < PMID: 22977477 > | Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweak‑induced apoptosis in PC‑3 prostate cancer cells. PLoS One. 2012; 7(10):e47440. < PMID: 23077618 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet